NEW YORK (GenomeWeb News) – Molecular diagnostics firm Provista Diagnostics today announced the completion of a Series B financing round that raised $6 million.
Existing investors participated in the round, which will be used to expand the company's commercial market development of dtectDx-Breast as Provista pursues 510(k) clearance of the assay. The firm also plans to conduct additional clinical trials for the test, which detects blood-based protein biomarkers that are "highly associated" with the development of breast cancer, it said on its website.
The Scottsdale, Ariz.-based firm also is developing dtectDx-Ovarian for ovarian cancer and dtectDx-Endo for endometrial/uterine cancer.
Provista previously raised $13.5 million in Series A financing.